Key Points
- Foghorn Therapeutics shares plummeted 49% to $1.84 following Eli Lilly’s decision to terminate their collaborative partnership.
- Both companies agreed to discontinue development of FHD-909 after Phase 1 trial data proved insufficient.
- An additional joint program targeting SMARCA2 degradation has also been terminated.
- The biotech firm is eliminating approximately 40% of its employees as part of a restructuring effort.
- Foghorn anticipates its remaining capital will sustain operations through late 2029.
Shares of Foghorn Therapeutics experienced a dramatic decline Thursday following the biotech company’s announcement that its collaboration with pharmaceutical giant Eli Lilly has been dissolved. The stock plunged 49% to $1.84 after trading resumed, representing the company’s most severe single-session decline in its history.
Foghorn Therapeutics Inc., FHTX
Shares were temporarily halted before the announcement. Once trading activity resumed, a wave of selling pressure hit the stock.
The biotechnology firm’s market capitalization now stands at approximately $212 million. This represents a dramatic downturn for a company that previously maintained a strategic alliance with one of the industry’s leading pharmaceutical corporations.
The partnership dissolution came after both organizations determined FHD-909 would not advance beyond its recently completed Phase 1 dose escalation study.
The experimental compound was engineered to inhibit the SMARCA2 protein through an oral small molecule approach. Its design centered on exploiting synthetic lethality in tumors harboring particular genetic mutations.
The Reason Behind Program Termination
Chief Executive Adrian Gottschalk explained that the compound successfully engaged its intended target. The safety profile also remained acceptable, even when administered at doses exceeding those predicted necessary by preclinical studies.
The critical shortcoming was clinical efficacy. According to Gottschalk, the underlying SMARCA2/4 biological interaction failed to produce clinical responses robust enough to justify continued development.
This represents a significant setback following extensive research and development efforts. The implications extend beyond a single therapeutic candidate.
Both organizations confirmed that a second joint initiative, focused on selective SMARCA2 degradation, will also be discontinued. Foghorn indicated it does not anticipate pursuing additional collaborative projects with Lilly.
The strategic alliance originated in December 2021, when Lilly’s Loxo Oncology division structured a deal featuring $300 million in initial payments combined with an $80 million equity investment at $20 per share.
Those financial arrangements appeared favorable for Foghorn initially. The current trading price stands drastically below that $20 valuation.
Foghorn’s Path Forward
Following the partnership’s conclusion, Foghorn has initiated significant cost reduction measures. The organization is eliminating nearly 40% of its workforce alongside broader operational restructuring.
Executive leadership projects these adjustments will extend the company’s financial runway through the latter portion of 2029. This timeline provides breathing room to advance remaining pipeline candidates.
Foghorn announced it will redirect resources toward wholly-owned proprietary programs. These assets include a selective EP300 degrader, a selective CBP degrader, and an oral therapeutic targeting immunology and inflammatory conditions.
The organization also plans to maintain its induced proximity platform as a strategic priority. These initiatives will proceed without Lilly’s financial backing.
For Eli Lilly, the market reaction was minimal. Its stock declined roughly 2%, a negligible movement for an entity of its scale.
For Foghorn, the consequences are far more substantial. The biotech now operates independently, relying on existing capital reserves and a streamlined organization to advance its development programs through the coming years.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
